Dermavant Sciences Revenue and Competitors
Estimated Revenue & Valuation
- Dermavant Sciences's estimated annual revenue is currently $81.4M per year.
- Dermavant Sciences received $100.0M in venture funding in August 2018.
- Dermavant Sciences's estimated revenue per employee is $217,000
- Dermavant Sciences has 375 Employees.
- Dermavant Sciences grew their employee count by 40% last year.
Dermavant Sciences Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Dermavant Sciences?
A Passion for Science and a Commitment to Dermatology Dermavant Sciences is a specialty biopharmaceutical company developing innovative prescription therapies for dermatologic diseases. Dermavant has acquired promising compounds that address unmet therapeutic needs and has rapidly established a robust dermatology R&D pipeline. We are dedicated to realizing the full potential of biomedical research and to developing and commercializing novel first-in-class or best-in-class therapies that improve patients lives. The patient is at the heart of everything we do.keywords:N/A
Number of Employees
Employee Growth %
Dermavant Sciences News
This year's SOCS Scientific Symposium was co-chaired by Andrew Alexis, MD, ... Beiersdorf, Dermavant Sciences, Ortho Dermatologics, P & G,...
Dermavant Sciences presented new data from the Phase III PSOARING 3 long-term extension study of tapinarof cream for plaque psoriasis in...
Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company dedicated to developing and...
Dermavant Sciences, a Long Beach CA, Durham, NC, and Basel, Switzerland-based biopharmaceutical company which specializes in immunodermatology therapy, raised $200M in funding. In details, the company has entered into: a $160m revenue interest purchase and sale agreement for its investigational ...
LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Mar 11, 2021-- Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that an abstract containing interim analysis data fr ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Dermavant Sciences Funding
|2018-08-29||$100.0M||Undisclosed||NovaQuest Capital Management||Article|